{"nctId":"NCT00479713","briefTitle":"A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)","startDateStruct":{"date":"2007-02-01","type":"ACTUAL"},"conditions":["Hypercholesterolemia"],"count":618,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: ezetimibe (+) simvastatin","Drug: Comparator: Placebo (unspecified)"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator : rosuvastatin calcium","Drug: Comparator: Placebo (unspecified)"]}],"interventions":[{"name":"ezetimibe (+) simvastatin","otherNames":["MK0653A","VytorinÂ®"]},{"name":"Comparator : rosuvastatin calcium","otherNames":[]},{"name":"Comparator: Placebo (unspecified)","otherNames":[]},{"name":"Comparator: Placebo (unspecified)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant is currently taking a statin medication for the treatment of high cholesterol\n* Participant has an LDL-C level that is greater than or equal to 100 mg/dl and less than or equal to 190 mg/dl\n\nExclusion Criteria:\n\n* Women who are pregnant or nursing, or women who intend to become pregnant\n* Participant has any condition, situation, or is currently taking any medication that might pose a risk to the participant or interfere with participation in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment","description":"Percent Change in LDL-C at study endpoint after six weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \\*100.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.66","spread":null},{"groupId":"OG001","value":"-16.94","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants Achieving Designated Low Density Lipoprotein-Cholesterol (LDL-C) Levels After 6 Weeks of Treatment","description":"The percentage of participants who achieved a target LDL-C goal of \\< 100 mg/dL, of \\<70 mg/dL, and of \\<77 mg/dL at study endpoint after six weeks of treatment.\n\nThe numerator is the number of participants in a treatment group who achieved a target LDL-C goal and the denominator is the total number of participants within that treatment group.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.46","spread":null},{"groupId":"OG001","value":"56.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.25","spread":null},{"groupId":"OG001","value":"11.11","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Total Cholesterol","description":"Percent change from baseline in total cholesterol at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \\*100.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.53","spread":null},{"groupId":"OG001","value":"-10.33","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Triglycerides.","description":"Percent change from baseline in triglycerides at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \\*100.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.00","spread":null},{"groupId":"OG001","value":"-5.26","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)","description":"Percent change from baseline in HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \\*100.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.12","spread":null},{"groupId":"OG001","value":"3.03","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)","description":"Percent change from baseline in non HDL-C at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \\*100.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.42","spread":null},{"groupId":"OG001","value":"-14.01","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio","description":"Percent change from baseline in LDL-C/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \\*100.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.41","spread":null},{"groupId":"OG001","value":"-17.82","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio","description":"Percent change from baseline in total cholesterol/HDL-C ratio at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \\*100.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.76","spread":null},{"groupId":"OG001","value":"-11.51","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Apolipoprotein B","description":"Percent change from baseline in apolipoprotein (Apo) B at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \\*100.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.87","spread":null},{"groupId":"OG001","value":"-9.77","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein","description":"Percent change from baseline in hs-C reactive protein at study endpoint after 6 weeks of treatment is calculated as the difference between week 6 measure and baseline measure divided by baseline measure \\*100.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3},"commonTop":["Myalgia","Abdominal pain","Diarrhoea","Dyspepsia","Abdominal pain upper"]}}}